Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
accepted:
26
02
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
An increasing number of women of reproductive age are treated with attention-deficit hyperactivity disorder (ADHD) medication; however, patterns of ADHD medication use for women in the perinatal period have not been well described. This study aimed to describe ADHD medication use patterns from 1 year before pregnancy to 1 year after delivery, and to describe sociodemographic characteristics and clinical features by medication trajectories. The population-based cohort study included pregnancies in Denmark between 1997 and 2020, from the Medical Birth Register, by women who filled at least one prescription for ADHD medication from 12 months before pregnancy until 12 months after delivery. We applied group-based trajectory modeling to classify women into subgroups based on the identification of heterogeneous ADHD medication treatment patterns, and described the characteristics associated with these groups. Overall, we included 4717 pregnancies leading to liveborn singletons by 4052 mothers with a mean (standard deviation) age of 27.5 (5.6) years. We identified four treatment trajectories across pregnancy and the postpartum period: continuers (23.3%), discontinuers (41.8%), interrupters who ceased filling prescriptions during pregnancy but resumed postpartum (17.2%), and postpartum initiators (17.7%). Continuers were older at the time of conception, gave birth in more recent years, were more likely to smoke during pregnancy, and used other psychotropic medications during pregnancy. A large proportion of continuers used methylphenidate (89.1%) compared with the other groups (75.9-84.1%) and had switched ADHD medication type during the whole period (16.4% vs. 7.4-14.8%). We found that approximately 60% of women discontinued or interrupted their ADHD medication around pregnancy, and those who continued differed in sociodemographic and clinical factors that may reflect more severe ADHD.
Sections du résumé
BACKGROUND
BACKGROUND
An increasing number of women of reproductive age are treated with attention-deficit hyperactivity disorder (ADHD) medication; however, patterns of ADHD medication use for women in the perinatal period have not been well described.
OBJECTIVE
OBJECTIVE
This study aimed to describe ADHD medication use patterns from 1 year before pregnancy to 1 year after delivery, and to describe sociodemographic characteristics and clinical features by medication trajectories.
METHODS
METHODS
The population-based cohort study included pregnancies in Denmark between 1997 and 2020, from the Medical Birth Register, by women who filled at least one prescription for ADHD medication from 12 months before pregnancy until 12 months after delivery. We applied group-based trajectory modeling to classify women into subgroups based on the identification of heterogeneous ADHD medication treatment patterns, and described the characteristics associated with these groups.
RESULTS
RESULTS
Overall, we included 4717 pregnancies leading to liveborn singletons by 4052 mothers with a mean (standard deviation) age of 27.5 (5.6) years. We identified four treatment trajectories across pregnancy and the postpartum period: continuers (23.3%), discontinuers (41.8%), interrupters who ceased filling prescriptions during pregnancy but resumed postpartum (17.2%), and postpartum initiators (17.7%). Continuers were older at the time of conception, gave birth in more recent years, were more likely to smoke during pregnancy, and used other psychotropic medications during pregnancy. A large proportion of continuers used methylphenidate (89.1%) compared with the other groups (75.9-84.1%) and had switched ADHD medication type during the whole period (16.4% vs. 7.4-14.8%).
CONCLUSION
CONCLUSIONS
We found that approximately 60% of women discontinued or interrupted their ADHD medication around pregnancy, and those who continued differed in sociodemographic and clinical factors that may reflect more severe ADHD.
Identifiants
pubmed: 38489019
doi: 10.1007/s40263-024-01076-1
pii: 10.1007/s40263-024-01076-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIMH NIH HHS
ID : R01MH122869
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. The Lancet. 2020;395(10222):450–62. https://doi.org/10.1016/S0140-6736(19)33004-1 .
doi: 10.1016/S0140-6736(19)33004-1
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8. https://doi.org/10.1176/ajp.2007.164.6.942 .
doi: 10.1176/ajp.2007.164.6.942
pubmed: 17541055
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23. https://doi.org/10.1176/ajp.2006.163.4.716 .
doi: 10.1176/ajp.2006.163.4.716
pubmed: 16585449
pmcid: 2859678
Sibley MH, Swanson JM, Arnold LE, Hechtman LT, Owens EB, Stehli A, et al. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. J Child Psychol Psychiatry. 2017;58(6):655–62. https://doi.org/10.1111/jcpp.12620 .
doi: 10.1111/jcpp.12620
pubmed: 27642116
Madsen KB, Ravn MH, Arnfred J, Olsen J, Rask CU, Obel C. Characteristics of undiagnosed children with parent-reported ADHD behaviour. Eur Child Adolesc Psychiatry. 2018;27(2):149–58. https://doi.org/10.1007/s00787-017-1029-4 .
doi: 10.1007/s00787-017-1029-4
pubmed: 28733915
Young S, Adamo N, Ásgeirsdóttir BB, Branney P, Beckett M, Colley W, et al. Females with ADHD: an expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. BMC Psychiatry. 2020;20(1):404. https://doi.org/10.1186/s12888-020-02707-9 .
doi: 10.1186/s12888-020-02707-9
pubmed: 32787804
pmcid: 7422602
Anderson KN, Ailes EC, Danielson M, Lind JN, Farr SL, Broussard CS, et al. Attention-deficit/hyperactivity disorder medication prescription claims among privately insured women aged 15–44 years—United States, 2003–2015. MMWR Morb Mortal Wkly Rep. 2018;67(2):66–70. https://doi.org/10.15585/mmwr.mm6702a3 .
doi: 10.15585/mmwr.mm6702a3
pubmed: 29346342
pmcid: 5772805
Kittel-Schneider S, Quednow BB, Leutritz AL, McNeill RV, Reif A. Parental ADHD in pregnancy and the postpartum period: a systematic review. Neurosci Biobehav Rev. 2021;124:63–77. https://doi.org/10.1016/j.neubiorev.2021.01.002 .
doi: 10.1016/j.neubiorev.2021.01.002
pubmed: 33516734
Østergaard SD, Dalsgaard S, Faraone SV, Munk-Olsen T, Laursen TM. Teenage parenthood and birth rates for individuals with and without attention-deficit/hyperactivity disorder: a nationwide cohort study. J Am Acad Child Adolesc Psychiatry. 2017;56(7):578–84. https://doi.org/10.1016/j.jaac.2017.05.003 . (e3).
doi: 10.1016/j.jaac.2017.05.003
pubmed: 28647009
Skoglund C, Kopp Kallner H, Skalkidou A, Wikström A-K, Lundin C, Hesselman S, et al. Association of attention-deficit/hyperactivity disorder with teenage birth among women and girls in Sweden. JAMA Netw Open. 2019;2(10): e1912463-e. https://doi.org/10.1001/jamanetworkopen.2019.12463 .
doi: 10.1001/jamanetworkopen.2019.12463
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–38. https://doi.org/10.1016/s2215-0366(18)30269-4 .
doi: 10.1016/s2215-0366(18)30269-4
pubmed: 30097390
pmcid: 6109107
Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res. 2020;123:21–30. https://doi.org/10.1016/j.jpsychires.2020.01.006 .
doi: 10.1016/j.jpsychires.2020.01.006
pubmed: 32014701
Baker AS, Freeman MP. Management of attention deficit hyperactivity disorder during pregnancy. Obstet Gynecol Clin North Am. 2018;45(3):495–509. https://doi.org/10.1016/j.ogc.2018.04.010 .
doi: 10.1016/j.ogc.2018.04.010
pubmed: 30092924
Karlstad Ø, Zoëga H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol. 2016;72(12):1507–14. https://doi.org/10.1007/s00228-016-2125-y .
doi: 10.1007/s00228-016-2125-y
pubmed: 27586399
pmcid: 5110707
Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010–2019. Eur J Clin Pharmacol. 2023;79(1):173–80. https://doi.org/10.1007/s00228-022-03428-6 .
doi: 10.1007/s00228-022-03428-6
pubmed: 36445458
McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519–52. https://doi.org/10.1177/0269881117699361 .
doi: 10.1177/0269881117699361
pubmed: 28440103
Srinivas C, Karlstad Ø, Stigum H, Furu K, Cesta CE, Reutfors J, et al. Trajectories of ADHD medication use before, during, and after pregnancy: a population-based study from Norway and Sweden. Pharmacoepidemiol Drug Saf. 2023;32(10):1152–60. https://doi.org/10.1002/pds.5654 .
doi: 10.1002/pds.5654
pubmed: 37309052
Trinh NTH, Munk-Olsen T, Wray NR, Bergink V, Nordeng HME, Lupattelli A, et al. Timing of antidepressant discontinuation during pregnancy and postpartum psychiatric outcomes in Denmark and Norway. JAMA Psychiat. 2023;80(5):441–50. https://doi.org/10.1001/jamapsychiatry.2023.0041 .
doi: 10.1001/jamapsychiatry.2023.0041
Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff-Roos J. The Danish medical birth register. Eur J Epidemiol. 2018;33(1):27–36. https://doi.org/10.1007/s10654-018-0356-1 .
doi: 10.1007/s10654-018-0356-1
pubmed: 29349587
Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2016;46(3):798-f. https://doi.org/10.1093/ije/dyw213 .
doi: 10.1093/ije/dyw213
Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW, et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023;28(4):1739–46. https://doi.org/10.1038/s41380-023-01992-6 .
doi: 10.1038/s41380-023-01992-6
pubmed: 36759544
Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health. 2011;39(7 Suppl):95–8. https://doi.org/10.1177/1403494811408483 .
doi: 10.1177/1403494811408483
pubmed: 21775363
Kronish IM, Rieckmann N, Halm EA, Shimbo D, Vorchheimer D, Haas DC, et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006;21(11):1178–83. https://doi.org/10.1111/j.1525-1497.2006.00586.x .
doi: 10.1111/j.1525-1497.2006.00586.x
pubmed: 16899061
pmcid: 1831650
Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29(3):374–93. https://doi.org/10.1177/0049124101029003005 .
doi: 10.1177/0049124101029003005
Herle M, Micali N, Abdulkadir M, Loos R, Bryant-Waugh R, Hübel C, et al. Identifying typical trajectories in longitudinal data: modelling strategies and interpretations. Eur J Epidemiol. 2020;35(3):205–22. https://doi.org/10.1007/s10654-020-00615-6 .
doi: 10.1007/s10654-020-00615-6
pubmed: 32140937
pmcid: 7154024
Meltzer-Brody S, Howard LM, Bergink V, Vigod S, Jones I, Munk-Olsen T, et al. Postpartum psychiatric disorders. Nat Rev Dis Primers. 2018;4:18022. https://doi.org/10.1038/nrdp.2018.22 .
doi: 10.1038/nrdp.2018.22
pubmed: 29695824
Jiang H-Y, Zhang X, Jiang C-M, Fu H-B. Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2019;28(3):288–95. https://doi.org/10.1002/pds.4716 .
doi: 10.1002/pds.4716
pubmed: 30585374
Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiat. 2018;75(2):167–75. https://doi.org/10.1001/jamapsychiatry.2017.3644 .
doi: 10.1001/jamapsychiatry.2017.3644
Li L, Sujan AC, Butwicka A, Chang Z, Cortese S, Quinn P, et al. Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS Drugs. 2020;34(7):731–47. https://doi.org/10.1007/s40263-020-00728-2 .
doi: 10.1007/s40263-020-00728-2
pubmed: 32333292
pmcid: 7338246
Harris GE, Wood M, Nordeng H. Modeling exposures of medications used episodically during pregnancy: triptans as a motivating example. Pharmacoepidemiol Drug Saf. 2020;29(9):1111–9. https://doi.org/10.1002/pds.5089 .
doi: 10.1002/pds.5089
pubmed: 32748540